ES2059299T1 - Metodo para el direccionado de un agente terapeutico a una poblacion especifica de celulas. - Google Patents

Metodo para el direccionado de un agente terapeutico a una poblacion especifica de celulas.

Info

Publication number
ES2059299T1
ES2059299T1 ES92902979T ES92902979T ES2059299T1 ES 2059299 T1 ES2059299 T1 ES 2059299T1 ES 92902979 T ES92902979 T ES 92902979T ES 92902979 T ES92902979 T ES 92902979T ES 2059299 T1 ES2059299 T1 ES 2059299T1
Authority
ES
Spain
Prior art keywords
therapeutic agent
addressing
cell population
specific cell
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES92902979T
Other languages
English (en)
Other versions
ES2059299T3 (es
Inventor
Lee Josephson
Ernest V Groman
Chu Jung
Jerome M Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Magnetics Inc
Original Assignee
Advanced Magnetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Magnetics Inc filed Critical Advanced Magnetics Inc
Publication of ES2059299T1 publication Critical patent/ES2059299T1/es
Application granted granted Critical
Publication of ES2059299T3 publication Critical patent/ES2059299T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

LA INVENCION SE REFIERE A UN METODO PARA EL OBJETIVO DE UN AGENTE TERAPEUTICO PARA UNA POBLACION ESPECIFICA DE CELULAS, EN DONDE ES FORMADO UN COMPLEJO ENTRE EL AGENTE TERAPEUTICO Y UN POLISACARIDO CAPAZ DE INTERACTUAR CON UN RECEPTOR DE LA CELULA Y EN DONDE EL COMPLEJO RESULTANTE ES INTERNADO DENTRO DE LA CELULA POR ENDOCITOSIS MEDIADA POR EL RECEPTOR (RMS). EN UNA REALIZACION DE LA INVENCION, UN COMPLEJO DE UN AGENTE TERAPEUTICO CONTENIENDO HIERRO Y ARABINOGALACTANO POLISACARIDO, PUEDE SER FORMADO Y USADO PARA SUMINISTRAR HIERRO ESPECIFICAMENTE A HEPATOCITOS POR RME.
ES92902979T 1990-12-19 1991-12-13 Direccionado de agentes terapeuticos utilizando polisacaridos. Expired - Lifetime ES2059299T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63001790A 1990-12-19 1990-12-19

Publications (2)

Publication Number Publication Date
ES2059299T1 true ES2059299T1 (es) 1994-11-16
ES2059299T3 ES2059299T3 (es) 1997-10-01

Family

ID=24525421

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92902979T Expired - Lifetime ES2059299T3 (es) 1990-12-19 1991-12-13 Direccionado de agentes terapeuticos utilizando polisacaridos.

Country Status (9)

Country Link
EP (1) EP0563249B1 (es)
JP (1) JP3357362B2 (es)
AT (1) ATE151991T1 (es)
CA (1) CA2097589C (es)
DE (2) DE69125848T2 (es)
DK (1) DK0563249T3 (es)
ES (1) ES2059299T3 (es)
GR (2) GR940300001T1 (es)
WO (1) WO1992011037A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
PT101422B (pt) * 1993-12-06 1997-06-30 Ineti Inst Biotec Q F E Tecnol Formulacoes lipossomicas contendo vidarabina e/ou derivados, com indice terapeutico elevado e processo para a sua preparacao
CA2242647A1 (en) 1996-01-10 1997-07-17 Amersham Health As Contrast media
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
FR2755976B1 (fr) 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
AU759016B2 (en) * 1998-10-05 2003-04-03 Penn State Research Foundation, The Compositions and methods for enhancing receptor-mediated cellular internalization
AU5085800A (en) * 1999-05-21 2000-12-12 Nycomed Imaging As Method of magnetic resonance imaging
GB9921579D0 (es) * 1999-09-13 1999-11-17 Nycomed Imaging As
US7082326B2 (en) 2000-03-31 2006-07-25 Amersham Health As Method of magnetic resonance imaging
CN1095472C (zh) * 2000-04-17 2002-12-04 上海复康医药科技发展有限公司 叶酸－多聚糖复合物，其制备方法和以该复合物为活性成分的药物组合物
IT1319665B1 (it) * 2000-11-17 2003-10-23 Pharma Biotech Ltd Addotti di corticosteroidi con polimeri polisaccaridici naturali.
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1724287A4 (en) * 2004-03-05 2010-10-27 Denki Kagaku Kogyo Kk HYALURONIC / METHOTREXATE CONNECTION
US7807675B2 (en) * 2004-04-02 2010-10-05 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid-methotrexate conjugate
JP2013053103A (ja) * 2011-09-05 2013-03-21 Ltt Bio-Pharma Co Ltd 薬物を封入した肝臓集積性ナノ粒子

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
EP0381742B1 (en) * 1988-08-04 1996-06-19 Advanced Magnetics Incorporated Receptor mediated endocytosis type mri contrast agents

Also Published As

Publication number Publication date
DE69125848T2 (de) 1997-07-31
EP0563249B1 (en) 1997-04-23
CA2097589A1 (en) 1992-06-20
WO1992011037A3 (en) 1992-08-06
DE69125848D1 (de) 1997-05-28
WO1992011037A2 (en) 1992-07-09
GR3023358T3 (en) 1997-08-29
DK0563249T3 (da) 1997-11-03
GR940300001T1 (en) 1994-02-28
JP3357362B2 (ja) 2002-12-16
CA2097589C (en) 1998-05-05
EP0563249A1 (en) 1993-10-06
JPH06503347A (ja) 1994-04-14
ATE151991T1 (de) 1997-05-15
DE563249T1 (de) 1994-03-03
ES2059299T3 (es) 1997-10-01

Similar Documents

Publication Publication Date Title
ES2059299T1 (es) Metodo para el direccionado de un agente terapeutico a una poblacion especifica de celulas.
CO4700414A1 (es) Barra antitranspirante clara que contiene alditol de diben- cilideno con hidroxialquil celulosa y/o agente quelante
ES2137372T3 (es) Solucion antifungica para las uñas.
DK0810857T3 (da) Colon-lægemiddelafgivelsessammensætning
EP0606790A3 (en) Doll or activated figure delivering a message of selected words, sentences or subjects.
DK0774005T3 (da) Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi
NO962088L (no) Preparat for in vivo-produksjon av terapeutiske produkter
AR020610A1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c segun la farmacopea us national formulary usp/nf, como agente de desagregacion y el procedimiento de fabricaion de un comprimido con dicho copolimero
EP0722324A4 (en) PHARMACEUTICAL COMPOSITION FOR IMMUNITIMULATING THERAPY
JO1273B1 (en) Compounds and Substitutes -2,3,4,5, Tetra-Idol-3-Benzazinate
ES2175968T3 (es) Complejo de platino, su preparacion y aplicacion terapeutica.
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
BR9610930A (pt) Composição depilatória incluindo uma quantidade funcional de um agente tixoitrópico, e, uso da quantidade funcional de um agente tixotrópico.
FR2713444B1 (fr) Composition liquide désinfectante et ses utilisations.
BR0013221A (pt) Chá preto de folha
AR246159A1 (es) Agente antiparasitario con accion mejorada.
ATE254851T1 (de) Iod-herstellungszusammensetzung
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
MX9102021A (es) Composiciones detergentes o blanqueadoras granuladas que contienen blanqueador de midoperoxiacido y perfume.
ZA9915B (en) Use of oxidation promoting chemicals in the oxidation of oxidizable galactose type of alcohol configuration containing polymer.
DK1237537T3 (da) Præparat i form af en gel til modtagelse af et aktivt stof i oplösning eller suspension, især til anvendelse på en slimhinde, og fremgangsmåde til dets fremstilling
YU180791A (sh) Injekcioni proizvod za sitni pesak i druge porozne materijale
AU1248602A (en) Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids
Candlin Principles and practice in communicative language teaching
JPS5219871A (en) Hydraulic buffer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 563249

Country of ref document: ES